Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f® in healthy women after follicle-stimulating hormone downregulation
Crossref DOI link: https://doi.org/10.1186/s12958-015-0124-y
Published Online: 2015-12-01
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lammerich, Andreas
Mueller, Arnd
Bias, Peter
Funding for this research was provided by:
BioGeneriX AG, now incorporated into Merckle GmbH, a member of the Teva group
Teva Branded Pharmaceutical Products R&D, Inc.
